Image 2_First-trimester choroid plexus-to-head ratio: a novel sonographic marker for the early detection of fetal central nervous system malformations.jpeg by Xianghua Xue (22563098)

“…Fetuses with microcephaly showed a significantly higher CPA/HA ratio (p < 0.001), higher CPL/OFD ratio (p < 0.001), and lower HC/AC ratio (p < 0.05).…”

Table 2_Following changes in brain structure and function with multimodal MRI in a year-long prospective study on the development of Type 2 diabetes.xlsx by Yingjie Wang (354135)

“…There were no significant changes in cognitive or motor behavior over the yearlong study but there was a significant increase in sensitivity to peripheral pain in diet fed rats. …”

Table 1_Following changes in brain structure and function with multimodal MRI in a year-long prospective study on the development of Type 2 diabetes.xlsx by Yingjie Wang (354135)

“…There were no significant changes in cognitive or motor behavior over the yearlong study but there was a significant increase in sensitivity to peripheral pain in diet fed rats. …”

DataSheet1_Positive vaccine beliefs linked to reduced mental stress in healthcare professionals during COVID-19: a retrospective study.pdf by Yu-Yin Lin (19690501)

“…Background and aim<p>The COVID-19 pandemic has led to a significant adverse effect on the mental health of healthcare professionals. …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Data Sheet 1_Analysis of serum amino acids and tryptophan metabolites to predict hepatic encephalopathy in portal hypertension patients receiving a transjugular intrahepatic portal... by Li Bao (323211)

“…</p>Results<p>We quantitatively determined 20 serum amino acids, and found that 4 amino acid levels were increased significantly in patients who complicated HE after TIPS. …”

Supplementary Material for: Real-World Insights into Avatrombopag’s Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central a... by figshare admin karger (2628495)

“…The primary endpoint was achieving a platelet response at Week 8. Results: AVA treatment resulted in a 68.3% platelet response rate by Week 8, with a significant increase in median platelet counts. …”

Image 1_Different lysine-to-methionine ratios in a low-protein diet affect the microbiome and metabolome, influencing the jejunal barrier function in Tibetan sheep.pdf by Fengshuo Zhang (20641988)

“…Furthermore, lowering the dietary Lys/ Met ratio significantly increased the abundance of Romboutsia, the Ruminococcus gauvreauii group, the Lachnospiraceae NK3A20 group, Ruminococcus 2, and the Christensenellaceae R-7 group (p < 0.05) while decreasing the abundance of Methanobrevibacter (p < 0.05). …”

Table 1_Different lysine-to-methionine ratios in a low-protein diet affect the microbiome and metabolome, influencing the jejunal barrier function in Tibetan sheep.docx by Fengshuo Zhang (20641988)

“…Furthermore, lowering the dietary Lys/ Met ratio significantly increased the abundance of Romboutsia, the Ruminococcus gauvreauii group, the Lachnospiraceae NK3A20 group, Ruminococcus 2, and the Christensenellaceae R-7 group (p < 0.05) while decreasing the abundance of Methanobrevibacter (p < 0.05). …”

Image 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 4_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

<i>ADH7, FABP5, ALDH1A1, CRABP-2, PPARγ</i> and <i>VEGFA</i> mRNA and ADH7, FABP5, CRABP-2, PPARγ and VEGFA protein levels in limbal stromal cells (LSCs) and aniridia limbal stroma... by Shuailin Li (11907158)

“…<i>ADH7, FABP5</i> and <i>VEGFA</i> mRNA levels were significantly higher in AN-LSCs, than in LSCs (p ≤ 0.037) while ADH7 protein level was significantly lower in AN-LSCs, than in LSCs (p = 0.022) <b>(A, B, D, O)</b>. …”